Genmab A (GMAB) Net Margin (2018 - 2026)
Genmab A (GMAB) reported Net Margin of 8.26% for Q1 2026, down 2587.0% on a YoY basis from 0.33% in Q1 2025, and down 82.49% quarter-over-quarter from 47.16% in Q3 2025.
Genmab A (GMAB) Net Margin (2018 - 2026) Analysis & Trends
Genmab A has reported Net Margin for 6 years, with the latest figure at 8.26% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 2587.0% year-over-year to 8.26%; the trailing twelve-month figure through Mar 2026 stood at 27.52% (down 8.0% YoY), and the FY2025 full-year result was 25.89%, down 1042.0% from the prior year.
- Net Margin for Q1 2026 stood at 8.26%, down from 47.16% in the prior quarter.
- The five-year high for Net Margin was 47.16% in Q3 2025, with the low at 8.26% in Q1 2026.
- Historically, Net Margin has averaged 35.28% across 3 years, with a median of 39.41% in 2024.
- Annual changes were most pronounced in 2025 — Net Margin jumped 1616 bps — and 2026, when it slumped 2587 bps.
- Genmab A's Net Margin stood at 31.0% in 2024, then jumped by 52 bps to 47.16% in 2025, then sank by 82 bps to 8.26% in 2026.
- The last three Net Margin figures came in at 8.26% (Q1 2026), 47.16% (Q3 2025), and 45.73% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | 8.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.26% |
| Sep 30, 2025 | 47.16% |
| Jun 30, 2025 | 45.73% |
| Mar 31, 2025 | 34.13% |
| Sep 30, 2024 | 31.00% |
| Jun 30, 2024 | 39.41% |
| Mar 31, 2024 | 41.29% |
| Sep 30, 2020 | 0.00% |
| Dec 31, 2019 | 67.21% |
| Sep 30, 2019 | 67,248,452.65% |
| Dec 31, 2018 | 38.52% |